Page results
-
Men currently attending a hospital outpatient clinic for prostate hormone injections every 3 or 6 months will be advised that (unless not clinically appropriate) their next injection will be administered at a local GP practice, usually by the practice nurse.
-
All semen analysis referrals should be made via the NHS e-Referral Service (e-RS). We will no longer be able to book semen analysis appointments through direct requests from patients or GP surgeries via email.
-
We are now administering new COVID-19 treatments for patients at highest risk in the community. The service can prescribe oral antivirals to be taken at home, and give intravenous antibody treatments at the hospital.
-
Contact details of clinical lead adults and lead paediatrics
-
Information for the Camden Sickle Cell and Thalassaemia Service
-
The spring/summer edition of Charity Matters is out now.
-
The UCLH and Great Ormond Street Hospital paediatric neuro-oncology service, which treats children with brain cancer, has been designated as one of six new ‘Tessa Jowell Centres of Excellence’.
-
People with obesity whose weight and health improve following drug treatment are likely to need the treatment long term, according to a UCLH and UCL study.
-
UCLH is delighted that His Majesty King Charles III has accepted the patronages of University College Hospital and the Royal London Hospital for Integrated Medicine.
File results
-
FOI/2024/0518 - Post partum balloons buying/ usage numbers
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer